CIIE veteran MitoQ moves into health management services in China

Summary

New Zealand cellular health brand MitoQ signed a strategic healthy ageing agreement with Yiling Medical Technology Group at the ninth China International Import Expo on 6 November, as three new products in its Cell Essentials range made their Asia debut the same day. The company, which has exhibited at all nine editions of the CIIE, is extending its China cooperation from products to health management services. Under the agreement, the two sides will build a full service system around cellular health, spanning professional testing, personalised programmes and ongoing follow-up.

Yiling Medical Technology Group brings more than 20 years of medical expertise and operational experience in the broader health sector, providing operational management and brand support to medical and wellness institutions and high-end aged-care providers globally. Kong Xiankai, director of industry development at the Boao Lecheng Administration, attended and witnessed the signing. The three products making their Asia debut were a marine fucoxanthin capsule, an equol women's balance capsule and a triple magnesium complex capsule.

The first product in the range, a high-purity fish oil, had its global launch at the 2024 CIIE. MitoQ's core ingredient, MitoQ® Mitoquinol (mitoquinol mesylate), has been recognised by Australia's Therapeutic Goods Administration and added to the list of permitted ingredients for listed complementary medicines in Australia. MitoQ chief executive Mahara Inglis said China is an important strategic market for the company's global growth and that it will continue to promote cellular health in daily life through product innovation and local partnerships.

MitoQ's China sales have grown at a double-digit rate for several consecutive years. Its technology stems from mitochondrial research at the University of Otago in New Zealand in the 1990s; the company launched its first branded product in 2012, entered the China market in 2017 and now sells to more than 100 countries and regions.

Commentary

MitoQ's shift from CIIE stalwart to health management services reflects an upgrade in China's health market from product competition to service ecosystems. New Zealand small and medium-sized enterprises should recognise that exporting supplements alone no longer meets Chinese consumers' demand for personalised, full-cycle health solutions. MitoQ's partnership with Yiling Medical, combining cellular health testing, intervention and follow-up, is a pragmatic route into China's high-end medical wellness and aged-care channels.

At the same time, TGA recognition of its core ingredient provides a compliance endorsement for entering more markets and is a reminder for New Zealand firms of the leverage international certification gives to brand trust. China's supplement market is growing at about 10 percent a year but is fiercely competitive, with local brands and cross-border e-commerce platforms holding substantial share. New Zealand companies relying solely on a 'pure' label may struggle to sustain growth.

MitoQ's nine consecutive years at the CIIE and double-digit growth show that deep local partnerships and scientific backing can build barriers. For New Zealand SMEs, the strategy offers lessons: build solutions with local service providers rather than merely selling products, and tap demand for preventive medicine created by China's ageing population by developing products for niche areas such as mitochondrial health and women's health. The CIIE also remains a low-cost window for SMEs to test market response.

Keywords: MitoQ, CIIE, healthy ageing strategic cooperation, cellular health, Yiling Medical Technology Group, Asia debut, TGA certification, Mahara Inglis


Image for illustration purposes

Source: shobserver.com

Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.

Leave a Reply

Your email address will not be published. Required fields are marked *